Following its recent failure to obtain accelerated approval from the FDA for its prostate cancer drug satraplatin, GPC Biotech AG has responded by cutting 46 positions at its Princeton, N.J., site, which represents approximately 15 percent of its payroll. (BioWorld International)

Following its recent failure to obtain accelerated approval from the FDA for its prostate cancer drug satraplatin, GPC Biotech AG has responded by cutting 46 positions at its Princeton, N.J., site, which represents approximately 15 percent of its payroll. (BioWorld International)